A Clinical Study on the Effect of Hibon-40(R): Riboflavin tetrabutyrate.
- Author:
Choun Ki JOO
1
;
Man Soo KIM
;
Jae Ho KIM
Author Information
1. Department of Ophthalmology, Kangnam St. Mary's Hospital, Catholic Medical College, Seoul, Korea.
- Publication Type:Original Article
- MeSH:
Arteriosclerosis;
Cataract;
Cause of Death;
Cholesterol;
Diabetic Retinopathy;
Eye Diseases;
Retina;
Riboflavin*;
Social Problems;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
1986;27(3):321-325
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Diseases caused by arteriosclerosis now occupy the first rank of the causes of death; they tend to increase further, and the countermeasure for adults' diseases is now noticed as one of big social problems. This study was devised to observe the effect of riboflavin tetrabutyrate on themetabolic changes in arteriosclerotic retinopathy, diabetic retinopathy, cataract and external eye diseases. After each case was treated three times daily for up to 13 weeks with riboflavin terabutyrate 120mg, we examined the visual acuity, retina changes, and cholesterol level at each visit. The results were as follows: 1. In arteriosclerotic retinopathy, visual improvement is noted in 44% of 18 cases and serum cholesterol level is decreased by 30.9mg/dl in average. 2. In diabetic retinopathy, visual improvement is noted in 37.5% of 16 cases and serum cholesterol level is decreased by 21.9mg/dl in average. 3. In cataract, visual improvement is noted in 8% of 12 cases and serum cholesterol level is reduced by 12.1mg/dl in average. 4. In external eye diseases, the symptoms and signs are much relieved.
